Business Wire

Affluent Medical Announces Significant Clinical Milestones with Two of Its Innovative Devices: ARTUS & KALIOS

Del

Affluent Medical, a new French medtech player specializing in innovative, minimally invasive implants designed to restore key physiological functions for patients suffering from heart and vascular diseases, as well as urinary incontinence, today announces significant clinical milestones for two of its innovative devices: ARTUS & KALIOS.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180601005256/en/

Kalios (Photo: Affluent Medical)

Kalios (Photo: Affluent Medical)

“We are excited about these key milestones since these studies are part of Affluent Medical’s clinical development plan, aiming at obtaining CE marking for each of our four products -KARDIOZIS, KALIOS, EPYGON and ARTUS, between the end of year 2020 / year 2022”, said Daniele Zanotti Affluent Medical’s CEO.

Successful start of the clinical trial with its ARTUS urinary implant

Affluent Medical has received authorization from the French regulatory agency on medical devices2 to carry out its first clinical trial in France. This clinical trial aims at demonstrating the safety and effectiveness of its urinary implant, ARTUS. This device intends on helping men and women suffering from severe urinary incontinence to recover full control of their bladders.

A similar clinical trial is already under way in the Czech Republic. ARTUS has been implanted in a first patient at the end of May 2018, at the Cochin Hospital. In this clinical trial, ARTUS will be temporarily implanted in a total of three women.

The clinical trial, entitled “Feasibility of the implantation of the ARTUS Artificial Urinary Sphincter in women,” in conducted at the Cochin Hospital in Paris. The ARTUS artificial urinary sphincter will be temporarily inserted in three women who have undergone a full urogenital tract ablation because of bladder cancer. The goal of the study is to verify, in the first place, that it is still possible to insert a catheter inside the bladder once the implant is in place. The study also aims at demonstrating the easy implementation and effectiveness of the device (adaptation to the neck of the bladder and activation of the implant).

ARTUS is an artificial urinary sphincter intended for both men and women. Fully concealable and easy to use via remote control, ARTUS will bring more comfort to patients by granting them easy control over their everyday urinary flow. Thanks to its optimized and adjustable pressure profile on the urethra, this device reduces the risk of decreased blood flow and tissue erosion of the urethra — two major complications experienced by patients with the artificial urinary sphincters currently available on the market.

A significant under-treated medical issue
Urinary incontinence affects one in four adults, with a female prevalence of 95%3. Yet, few implants are designed to help women recover control of their bladder. Men who have had their prostates removed or are treated for severe incontinence have more access to artificial sphincters; while women, who are the most affected by this pathology, are treated minimally or not at all due to a lack of products adapted to their anatomies. According to a study by IMS Consulting Group, in Western countries, only 3% of all artificial sphincter procedures involved women3.

This is therefore a large market, combined with a truly unmet medical need to date. ARTUS aims at becoming the next standard of care in this market. The total global turnover of this market, in the field of urology, is today estimated at $ 7 billion per year in 2020, with a potential annual growth rate of 26% between 2017-20204.

ARTUS, a promising implant to be launched by 2021 in Europe

Video presentation: https://www.youtube.com/watch?v=-l1W1_sgMiM&feature=youtu.be

Currently in clinical phase with ARTUS, Affluent Medical is planning a first market launch in Europe in 2021.Various studies in technical feasibility, safety, tolerance and efficiency have already been conducted both on animals and in laboratory. ARTUS has been clinically tested in Czech Republic, since February 28, 2018, at the Thomayer Hospital in Prague, under the same conditions as the upcoming study in France. A pivotal CE marking trial, which should involve 35 patients suffering from severe urinary incontinence, is planned for the end of 2018. Affluent Medical is also considering a trial in male patients by the end of 2019.

Completion of enrollment in a feasibility study for KALIOS

The implantation of the device in a fifth and last patient has been performed at the end of May 2018 by Prof. Martin Andreas, Principal Investigator of the study, at the Vienna General Hospital (AKH). The first results of the study, aiming at testing the feasibility and surgical safety of KALIOS, are expected in Q2 2018.

KALIOS can treat both residual postoperative leaks and chronic mitral insufficiency. The size and shape of the implant can be adjusted percutaneously multiple times in the months/years following the surgery, offering patients a personalized surgical treatment.

The European launch of the device is scheduled for the end of 2020, subject to the obtention of the necessary marketing authorizations. It targets a total global market expected to reach $3.5 billion by 2022 and growing at a rate of 35% per year between 2017-2022(5).

About Affluent Medical

Affluent Medical is a new French medtech player with the ambition to become one of the European leaders in the treatment of heart and vascular diseases - which are the leading cause of death throughout the world - and of urinary incontinence today affecting one in four adults, subject to the achievement of complementary steps and obtention of marketing authorization. Affluent Medical is developing innovative, next-generation minimally invasive implants to restore key physiological functions in these areas. The company’s four medical devices are currently in preclinical and clinical validation phases, and a first medical device is expected to be launched by 2020.

Affluent Medical was born in February 2018, from the combination of four technologies drawn from Truffle Capital’s portfolio: KARDIOZIS, KALIOS, EPYGON and ARTUS.

Affluent Medical announced it was planning an initial public offering on the Euronext Growth market in Paris and filed a Document de Base with the Autorité des marchés financiers (AMF) on May 28, 2018, with registration number I. 18-045.

For more information: www.affluentmedical.com

Disclaimer

This press release and the information it contains do not constitute an offer to sell or to subscribe, or a solicitation to purchase or subscribe shares in Affluent Medical.

The release, publication or distribution of this press release in certain jurisdictions may be restricted by laws or regulations. Persons in such jurisdictions into which this press release is released, published or distributed must inform themselves about and comply with such laws or regulations.

This press release is a promotional message and not a prospectus in the meaning of Directive 2003/71/EC of the European Parliament and Council dated 4 November 2003, as amended (the “Prospectus Directive”).

This press release does not constitute or form part of an offer of securities or a solicitation for purchase, subscription or sale of securities in the United States. Securities may not be offered, subscribed or sold in the United States without registration under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”,) and other applicable state securities law, except pursuant to an exemption from registration. Affluent Medical shares have not been and will not be registered under the U.S. Securities Act, and Affluent Medical does not intend to undertake a public offering of its securities in the United States.

With respect to the member states of the European Economic Area other than France (the “Member States”) having implemented the Prospectus Directive into law, no action has been or will be taken in order to permit a public offer of the securities which would require the publication of a prospectus in one of such Member States. As a result, the securities of Affluent Medical may not and will not be offered in any Member State other than France, except in accordance with the exemptions set forth in Article 3 of the Prospectus Directive, if they have been implemented in the relevant member states or in the other case which does not require the publication by Affluent Medical of a prospectus pursuant to the Prospectus Directive and/or applicable regulation in the member states.

This press release does not contain or constitute an invitation, inducement or solicitation to invest. This press release is intended solely for persons (1) who are not in the United Kingdom; (2) who are investment professionals within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 as amended (the “Order”); or (3) who are « high net worth entities », and other persons falling within the provisions of Article 49 (2) (a) to (d) of the Order (those persons cited in (1), (2) and (3) together being designated as “Relevant Persons”).

This press release is aimed solely at Relevant Persons. Any investment or investment activity in connection with this press release is reserved solely for Relevant Persons and may only be made by Relevant Persons.

Not for release, publication or distribution, directly or indirectly, in the United States, Australia, Canada or Japan.

1 Subject to the obtention of necessary marketing authorizations.
2 ANSM: Agence Nationale de Sécurité du Médicament et des produits de santé
3 Source: IMS Consulting Group Study - 2014: US Market Opportunity Assessment for ARTUS
4 Source: Boston Scientific, Presentation Investor Day 2017, June 27 2017
5 Azoth Analytics – 2017: Transcatheter Mitral Valve Repair and Replacement (TMVR) Market – Opportunities and Forecast 2017-2022

Contact information

Affluent Medical
Henri Lefebvre, Chief Financial Officer
investor@affluentmedical.com
Tel.: +33-(0)1-82-28-46-00
or
Press
ALIZE RP
Caroline Carmagnol & Wendy Rigal
affluentmedical@alizerp.com
Tel.: +33-(0)1-44-54-36-66

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza16.8.2018 05:00Pressemelding

BioNTech AG, a rapidly growing biotechnology company focused on precise immunotherapies for the treatment of cancer and infectious disease, today announced that it has entered into a multi-year research and development (R&D) collaboration with Pfizer Inc. (NYSE: PFE) to develop mRNA-based vaccines for prevention of influenza (flu). Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for further clinical development and commercialization of mRNA-based flu vaccines, following BioNTech’s completion of a first in human clinical study. BioNTech will receive $120 million in upfront, equity and near-term research payments and up to an additional $305 million in potential development, regulatory and commercial milestone payments. In addition, BioNTech will receive up to double-digit tiered royalty payments associated with worldwide sales if the program reac

Maxion Wheels to Showcase Market-Leading Light Weight Commercial Vehicle Wheels at REIFEN 201816.8.2018 04:05Pressemelding

Maxion Wheels, the world’s largest producer of wheels, announced today its participation in REIFEN, the leading tire and wheel industry event in Europe, from Sept. 11 – 15, 2018 in Hall 12.1 / Stand D24. For the first time, REIFEN will be co-located with Automechanika Frankfurt at the Messe Frankfurt. “REIFEN is the premier event for European tire and wheel manufacturers and resellers, bringing us together to meet and collaborate on the important aftermarket themes of innovation, service and delivery,” stated Mark Gerardts, Vice President of Global Sales and Marketing, Maxion Wheels. “After a highly popular launch to truck and trailer OEMs in 2017, we’re excited to have the industry’s lightest mass production steel wheel now available to our aftermarket distributors. This wheel, along with several others, including our new 10.00W-20 wide base tubetype and tubeless heavy duty armored vehicles wheel are great examples of our continued efforts to bring our OE multi-application innovations

Lenovo Accelerates Turnaround with Back-to-Back, Double-Digit Quarterly Revenue Growth15.8.2018 23:40Pressemelding

Lenovo Group (HKSE: 0992) (PINK SHEETS: LNVGY) today announced results for its first fiscal quarter ended June 30, 2018. For the second straight quarter, Lenovo achieved strong double-digit growth in revenue year-on-year. Group revenue reached US$11.91 billion, up 19% year-on-year. The company also reported strong pre-tax income during the quarter of US$113 million, an improvement of US$182 million year-on-year, as profitability improved across all businesses. In the first fiscal quarter, Lenovo’s profit attributable to equity holders grew to US$77 million, up US$149 million year-over-year. Basic earnings per share in the first fiscal quarter was 0.65 US cents or 5.10 HK cents. “As we persistently execute our 3-wave strategy, all our businesses made solid improvements in both revenue and profitability. Lenovo has passed the turning point and entered a phase of ‘acceleration’ - accelerating the execution of our transformation strategy and accelerating the rising momentum in business per

CORRECTING and REPLACING Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 22:37Pressemelding

Please replace the release with the following corrected version due to multiple revisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) The corrected release reads: EBOLA SUCCESSFULLY NEUTRALIZED BY LATEST GENERATION POLYCLONAL IMMUNOTHERAPY Promising new platform can rapidly respond to emerging infectious diseases Sioux Falls, SD, August 15, 2018 – SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted at the Integrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of He

Ebola Successfully Neutralized by Latest Generation Polyclonal Immunotherapy15.8.2018 17:43Pressemelding

SAB Biotherapeutics, Inc. (SAB), a clinical-stage biopharmaceutical company, today announced that its anti-Ebola immunotherapy (SAB-139) provided “100% protection against a lethal dose of the Ebola virus” in a recent animal study published in The Journal of Infectious Diseases . The study was conducted by the National Interagency Confederation for Biological Research and other collaborators including United States Army Medical Research Institute of Infectious Diseases (USAMRIID) and the Naval Medical Research Center (NMRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005602/en/ New Ebola immunotherapy developed by SAB Biotherapeutics uses natural human polyclonal antibodies to combat disease. (Photo: SAB Biotherapeutics) According to the World Health Organization, Ebola virus disease (EVD), formerly known as Ebola hemorrhagic fever, is a severe, often fatal illness in humans with an average fatality rate around 50%.

Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovation15.8.2018 17:05Pressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced it has been honored with a Stevie® Award in the Innovation in Customer Service Management, Planning & Practice category for its ultra-responsive, premium level service in the Asia-Pacific region. This honor marks the Company’s 12th Stevie Award win this year, and the second consecutive year the Company has been recognized by the Asia-Pacific Stevie Awards. Rimini Street recently earned Stevie Awards in several categories, including Company of the Year from the 2018 American Business Awards® and Customer Service Department of the Year from the 2018 Stevie Awards for Sales & Customer Service. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180815005580/en/ Rimini Street Receives Asia-Pacific Stevie Award for Customer Service Innovat